Core Viewpoint - InMed Pharmaceuticals is facing potential negative impacts on its subsidiary BayMedica due to the recently signed H.R. 5371 Act, which may prohibit certain aspects of BayMedica's commercial business if enforced in its current form [3][5]. Group 1: Impact of the Act - The Act could materially affect BayMedica's inventory of rare, non-intoxicating cannabinoids, which may be prohibited under the new legislation set to take effect on November 12, 2026 [3][5]. - InMed is currently evaluating alternative supply chain options to ensure regulatory compliance for BayMedica [3][6]. - The company acknowledges uncertainty regarding whether the sections of the Act impacting BayMedica will ultimately be enforced or amended before the effective date [5]. Group 2: Commitment to Core Programs - Despite the potential challenges posed by the Act, InMed remains focused on its core pharmaceutical drug development programs, which are not affected by the new legislation [4]. - The company continues to advance its drug candidates, including INM-901 for Alzheimer's disease and INM-089 for age-related macular degeneration [4]. Group 3: Ongoing Operations - BayMedica is continuing its normal business operations while evaluating the potential impact of the Act, with no set timetable for concluding its evaluation or making definitive decisions on alternative options [6].